[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330385-105":59,"doc-detail-330385-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","new-hopes-for-the-breast-cancer-treatment-perspectives-on-the-oncolytic-virus-therapy","New hopes for the breast cancer treatment - perspectives on the oncolytic virus therapy","","Oncolytic virus (OV) therapy is presented as a promising frontier for solid tumours, including breast cancer, in the context of the remaining limitations of immune checkpoint inhibitors and CAR‑T cells. OVs selectively replicate in cancer cells, lyse tumours, remodel the tumour microenvironment, and can synergize with other treatments such as chemotherapy, radiotherapy, and immunotherapy. Multiple engineered viruses are discussed, along with clinical experience and reported adverse effects, while breast cancer-specific approvals are still lacking. The review highlights ongoing preclinical and clinical directions.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-hopes-for-the-breast-cancer-treatment-perspectives-on-the-oncolytic-virus-therapy/330385/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-hopes-for-the-breast-cancer-treatment-perspectives-on-the-oncolytic-virus-therapy/330385.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"Why is oncolytic virus (OV) therapy being explored for breast cancer?","Question",{"text":113,"@type":114},"Because existing immunotherapies such as immune checkpoint inhibitors and CAR‑T cells have limited ability to achieve complete tumour regression for some patients, motivating new strategies targeting resistant tumours.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},330385,1790014999,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":137,"read_time":138},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 21 March 2024  \nDOI 10.3389/fimmu.2024.1375433  \nOPEN ACCESS  \nEDITED BY  \nDon J. Diamond,  \nCity of Hope National Medical Center, United States  \nREVIEWED BY Peng Qu,  \nNational Institutes of Health (NIH), United States  \nGuohao Wang,  \nNational Institutes of Health (NIH), United States  \n*CORRESPONDENCE Hanna Chowaniec  \n [hanna.chowaniec@gmail.com](hanna.chowaniec@gmail.com)  \nRECEIVED 23 January 2024  \nACCEPTED 11 March 2024  \nPUBLISHED 21 March 2024  \nCITATION  \nChowaniec H, S´lubowska A, Mroczek M, Borowczyk M, Braszka M, Dworacki G, Dobosz P and Wichtowski M (2024) New hopes for the breast cancer treatment:  \nperspectives on the oncolytic virus therapy. Front. Immunol. 15:1375433 .  \ndoi: 10.3389/fimmu.2024.1375433  \nCOPYRIGHT  \n© 2024 Chowaniec, S´lubowska, Mroczek, Borowczyk, Braszka, Dworacki, Dobosz and Wichtowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nNew hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy  \nHanna Chowaniec 1*, Antonina ´Slubowska 2, Magdalena Mroczek 3, Martyna Borowczyk 4,  \nMałgorzata Braszka 5, Grzegorz Dworacki 1,6, Paula Dobosz 7,8 and Mateusz Wichtowski 9  \n1 Department of Immunology, Poznan University of Medical Sciences, Poznan, Poland, 2 Department of Biostatistics and Research Methodology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University of Warsaw, Warsaw, Poland, 3 Department of Neurology, University Hospital Basel, Univeristy of Basel, Basel, Switzerland, 4 Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland, 5 Faculty of Medical Sciences, University College London Medical School, London, United Kingdom, 6Chair of Patomorphology and Clinical Immunology, Poznan´ University of Medical Sciences, Poznan, Poland, 7 University Centre of Cancer Diagnostics, Poznan University of Medical Sciences, Poznan, Poland, 8 Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland, 9Surgical Oncology Clinic, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland  \nOncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1) . These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties. Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, an","cbCaib4umWeKOns8","https://ap.wps.com/l/cbCaib4umWeKOns8","pdf",752566,17,"English","# Introduction\n## Oncolytic viruses and immunotherapy limitations","[{\"question\":\"Why is oncolytic virus (OV) therapy being explored for breast cancer?\",\"answer\":\"Because existing immunotherapies such as immune checkpoint inhibitors and CAR‑T cells have limited ability to achieve complete tumour regression for some patients, motivating new strategies targeting resistant tumours.\"}]","New hopes for the breast cancer treatment - perspectives on the oncolytic virus therapy | PDF",1789988575,43]